NVIC

Janssen/Johnson & Johnson COVID-19 and Transverse Myelitis

Published November 10, 2021

In January 2022, the Pharmacovigilance and Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) reported that a reasonable association existed between the Janssen/Johnson & Johnson and AstraZeneca, an additional adenovirus vector COVID-19 vaccine and transverse myelitis (TM), a rare but serious condition that involves inflammation of the spinal cord. Symptoms of TM include tingling, numbness, pain or loss of pain sensation, limb weakness, and issues with bowel and bladder function. According to PRAC, 38 cases of TM have been reported following adenovirus vector vaccines – 25 following the AstraZeneca COVID-19 vaccine and 13 following the Johnson & Johnson/Janssen vaccine.169

Select disease / vaccine